Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects

FASEB Journal

Volumn 29, Issue 8, 2015, Pages 3193-3205

  Strandgren, Charlotte ^a   Nasser, Hasina Abdul ^a   McKenna, Tomás ^a   Koskela, Antti ^a   Tuukkanen, Juha ^a   Ohlsson, Claes ^b   Rozell, Björn ^c,d   Eriksson, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF OULU   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Lamin A C; Nuclear lamina; Osteoblasts; Osteocytes; Premature aging

Indexed keywords

DOXYCYCLINE; HUTCHINSON GILFORD PROGERIA SYNDROME PROTEIN; LAMIN A; RESVERATROL; RNA; UNCLASSIFIED DRUG; STILBENE DERIVATIVE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BONE MARROW; BONE MINERALIZATION; BONE REMODELING; BONE STRENGTH; BONE STRUCTURE; CALLUS; CELL DENSITY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CORTICAL BONE; DRUG EFFECT; FEMALE; GENE MUTATION; GENE REPRESSION; GENE SILENCING; GENE TARGETING; GENOTYPE; INCISOR; MALE; MOUSE; NEWBORN; NONHUMAN; ODONTOBLAST; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROGERIA; QUANTITATIVE ANALYSIS; RIB FRACTURE; RNA SPLICING; THORAX; TOOTH DEVELOPMENT; TRANSGENE; TRANSGENIC MOUSE; TREATMENT DURATION; WEIGHT GAIN; WHITE ADIPOCYTE; ANIMAL; BONE; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; PHYSIOLOGY;

MUS;

ANIMALS; BONE AND BONES; FEMALE; GENE SILENCING; LAMIN TYPE A; MALE; MICE; MUTATION; OSTEOCYTES; PHENOTYPE; PROGERIA; STILBENES; TRANSGENES;

EID: 84940399428     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-269217     Document Type: Article

References (39)

1. DeBusk, F. L. (1972) The Hutchinson-Gilford progeria syndrome. Report of 4 cases and review of the literature. J. Pediatr. 80, 697-724
2. Hennekam, R. C. (2006) Hutchinson-Gilford progeria syndrome: review of the phenotype. Am. J. Med. Genet. A. 140, 2603-2624
3. Merideth, M. A.,Gordon,L. B.,Clauss, S., Sachdev, V., Smith, A. C., Perry, M. B., Brewer, C. C., Zalewski, C., Kim, H. J., Solomon, B., Brooks, B. P., Gerber, L. H., Turner, M. L., Domingo, D. L., Hart, T. C., Graf, J., Reynolds, J. C., Gropman, A., Yanovski, J. A., Gerhard-Herman, M., Collins, F. S., Nabel, E. G., Cannon III, R. O., Gahl, W. A., and Introne, W. J. (2008) Phenotype and course of Hutchinson-Gilfordprogeria syndrome. N. Engl. J. Med. 358, 592-604
4. Gordon,C.M., Gordon, L.B., Snyder, B.D.,Nazarian,A.,Quinn,N., Huh, S., Giobbie-Hurder, A., Neuberg, D., Cleveland, R., Kleinman, M., Miller, D. T., and Kieran, M. W. (2011) Hutchinson-Gilford progeria is a skeletal dysplasia. J. Bone Miner. Res. 26, 1670-1679
5. Gordon, L. B.,McCarten, K. M.,Giobbie-Hurder,A.,Machan, J. T., Campbell, S. E., Berns, S. D., and Kieran, M. W. (2007) Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 120, 824-833
6. De Sandre-Giovannoli, A.,Bernard,R., Cau, P.,Navarro,C.,Amiel, J., Boccaccio, I., Lyonnet, S., Stewart,C. L.,Munnich,A., LeMerrer,M., and Lévy, N. (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300, 2055
7. Eriksson, M., Brown, W. T., Gordon, L. B., Glynn, M. W., Singer, J., Scott, L., Erdos, M. R., Robbins, C. M., Moses, T. Y., Berglund, P., Dutra, A., Pak, E., Durkin, S., Csoka, A. B., Boehnke, M., Glover, T.W., and Collins, F. S. (2003) Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 423, 293-298
8. Fong, L. G., Frost, D., Meta, M., Qiao, X., Yang, S. H., Coffinier, C., and Young, S. G. (2006) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311, 1621-1623
9. Yang, S. H., Meta, M., Qiao, X., Frost, D., Bauch, J., Coffinier, C., Majumdar, S., Bergo, M. O., Young, S. G., and Fong, L. G. (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J. Clin. Invest. 116, 2115-2121
10. Capell,B.C.,Olive,M., Erdos,M. R.,Cao,K., Faddah,D.A., Tavarez, U. L., Conneely, K. N., Qu, X., San, H., Ganesh, S. K., Chen, X., Avallone, H., Kolodgie, F. D., Virmani, R., Nabel, E. G., and Collins, F. S. (2008) A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc. Natl. Acad. Sci. USA 105, 15902-15907
11. Osorio,F.G.,Navarro,C.L.,Cadinanos, J.,Lopez-Mejia, I.C.,Quiros, P.M., Bartoli,C., Rivera, J., Tazi, J., Guzman,G., Varela, I.,Depetris, D., de Carlos, F., Cobo, J., Andres, V., De Sandre-Giovannoli, A., Freije, J. M., Levy, N., and Lopez-Otin, C. (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci. Transl. Med. 3, 106ra107
12. Varela, I., Pereira, S.,Ugalde,A. P.,Navarro,C. L., Suárez,M. F.,Cau, P., Cadiñanos, J.,Osorio, F.G.,Foray,N., Cobo, J., deCarlos,F., Lévy, N., Freije, J.M., and López-Otn , C. (2008)Combined treatmentwith statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat. Med. 14, 767-772
13. Toth, J. I., Yang, S. H., Qiao, X., Beigneux, A. P., Gelb, M. H., Moulson, C. L., Miner, J. H., Young, S. G., and Fong, L. G. (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts fromhumans with progeroid syndromes. Proc. Natl. Acad. Sci. USA 102, 12873-12878
14. Glynn, M. W., and Glover, T. W. (2005) Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum. Mol. Genet. 14, 2959-2969
15. Capell, B. C., Erdos, M. R., Madigan, J. P., Fiordalisi, J. J., Varga, R., Conneely, K. N.,Gordon, L. B.,Der,C. J., Cox, A.D., and Collins, F. S. (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc.Natl. Acad. Sci. USA 102, 12879-12884
16. Mallampalli, M. P., Huyer, G., Bendale, P., Gelb, M. H., and Michaelis, S. (2005) Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 102, 14416-14421
17. Gordon, L. B., Kleinman, M. E., Miller, D. T., Neuberg, D. S., Giobbie-Hurder, A., Gerhard-Herman, M., Smoot, L. B., Gordon, C. M., Cleveland, R., Snyder, B. D., Fligor, B., Bishop, W. R., Statkevich, P., Regen, A., Sonis, A., Riley, S., Ploski, C., Correia, A., Quinn, N., Ullrich, N. J., Nazarian, A., Liang, M. G., Huh, S. Y., Schwartzman, A., and Kieran, M. W. (2012) Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 109, 16666-16671
18. Gordon, L.B.,Rothman, F.G., López-Otn ,C., and Misteli,T. (2014) Progeria: a paradigm for translational medicine. Cell 156, 400-407
19. Lavu, S., Boss, O., Elliott, P. J., and Lambert, P. D. (2008) Sirtuins-novel therapeutic targets to treat age-Associated diseases. Nat. Rev. Drug Discov. 7, 841-853
20. Liu, B., Ghosh, S., Yang, X., Zheng, H., Liu, X., Wang, Z., Jin, G., Zheng, B., Kennedy, B. K., Suh, Y., Kaeberlein, M., Tryggvason, K., and Zhou, Z. (2012) Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathybased progeria. Cell Metab. 16, 738-750
21. Karimian, E., Tamm, C., Chagin, A. S., Samuelsson, K., Kjartansdóttir, K. R., Ohlsson, C., and Sävendahl, L. (2013) Resveratrol treatment delays growth plate fusion and improves bone growth in female rabbits. PLoS One 8, e67859
22. Schmidt, E., Nilsson, O., Koskela, A., Tuukkanen, J., Ohlsson, C., Rozell, B., and Eriksson, M. (2012) Expression of the Hutchinson-Gilford progeria mutation during osteoblast development results in loss of osteocytes, irregularmineralization, and poor biomechanical properties. J. Biol. Chem. 287, 33512-33522
23. Sagelius, H., Rosengardten, Y., Hanif, M., Erdos, M. R., Rozell, B., Collins, F. S., and Eriksson, M. (2008) Targeted transgenic expression of the mutation causing Hutchinson-Gilford progeria syndrome leads to proliferative and degenerative epidermal disease. J. Cell Sci. 121, 969-978
24. Rodda, S. J., and McMahon, A. P. (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133, 3231-3244
25. Baek, J. H., Schmidt, E., Viceconte, N., Strandgren, C., Pernold, K., Richard, T. J., Van Leeuwen, F. W., Dantuma, N. P., Damberg, P., Hultenby, K.,Ulfhake, B., Mugnaini, E., Rozell, B., and Eriksson, M. (2015) Expression of progerin in aging mouse brains reveals structural nuclear abnormalities without detectible significant alterations in gene expression, hippocampal stem cells or behavior. Hum. Mol. Genet. 24, 1305-1321
26. Gordon, B. S., Delgado Daz, D. C., and Kostek, M. C. (2013) Resveratrol decreases inflammation and increases utrophin gene expression in the mdx mouse model of Duchenne muscular dystrophy. Clin. Nutr. 32, 104-111
27. McKenna,T.,Rosengardten, Y.,Viceconte,N.,Baek, J.H.,Grochová, D., and Eriksson, M. (2014) Embryonic expression of the common progeroid lamin A splice mutation arrests postnatal skin development. Aging Cell 13, 292-302
28. Rosengardten, Y., McKenna, T., Grochová, D., and Eriksson, M. (2011) Stem cell depletion in Hutchinson-Gilford progeria syndrome. Aging Cell 10, 1011-1020
29. Windahl, S. H., Vidal, O., Andersson, G., Gustafsson, J. A., and Ohlsson, C. (1999) Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. J. Clin. Invest. 104, 895-901
30. Mansour, A.,Abou-Ezzi,G., Sitnicka,E., Jacobsen, S. E.,Wakkach, A., and Blin-Wakkach, C. (2012) Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow. J. Exp. Med. 209, 537-549
31. Varga, R., Eriksson, M., Erdos, M. R., Olive, M., Harten, I., Kolodgie, F., Capell, B. C., Cheng, J., Faddah, D., Perkins, S., Avallone, H., San, H., Qu, X., Ganesh, S., Gordon, L. B., Virmani, R.,Wight, T. N., Nabel, E. G., and Collins, F. S. (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc. Natl. Acad. Sci. USA 103, 3250-3255
32. Sagelius, H., Rosengardten, Y., Schmidt, E., Sonnabend, C., Rozell, B., and Eriksson,M. (2008)Reversible phenotype in amousemodel ofHutchinson-Gilfordprogeria syndrome. J.Med.Genet. 45, 794-801
33. Gall, G. A., and Kyle,W. H. (1968) Growth of the laboratory mouse. Theor. Appl. Genet. 38, 304-308
34. Coady, J.M., Toto, P. D., and Santangelo, M. V. (1967) Histology of the mouse incisor. J. Dent. Res. 46, 384-388
35. Zegarelli, E. V. (1944) Adamantoblastomas in the Slye Stock ofMice. Am. J. Pathol. 20, 23-87
36. Zhou, X., von der Mark, K., Henry, S., Norton, W., Adams, H., and de Crombrugghe, B. (2014) Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. PLoS Genet. 10, e1004820
37. Ono, N., Ono, W., Nagasawa, T., and Kronenberg, H. M. (2014) A subset of chondrogenic cells provides early mesenchymal progenitors in growing bones. Nat. Cell Biol. 16, 1157-1167
38. Devlin,M. J.,Cloutier,A.M.,Thomas,N.A.,Panus,D.A., Lotinun,S., Pinz, I., Baron, R., Rosen, C. J., and Bouxsein, M. L. (2010) Caloric restriction leads to high marrow adiposity and low bone mass in growing mice. J. Bone Miner. Res. 25, 2078-2088
39. Finley, J. (2014) Alteration of splice site selection in the LMNA gene and inhibition of progerin production via AMPK activation. Med. Hypotheses 83, 580-587